山东省羊羔疯病中医专业医院(青岛哪里治癫痫不错) (今日更新中)

BEIJING, Jan. 12 (Xinhua) -- China's consumer price index (CPI), a main gauge of inflation, rose 4.1 percent year-on-year in December, down 0.1 percentage point from November on falling non-food prices, the National Bureau of Statistics (NBS) said Thursday.The CPI was up 5.4 percent in 2011 from the previous year, well above the government's full-year inflation control target of 4 percent, the NBS said in a statement on its website.The inflation rate in December marked a five-straight-month decline after hitting a 37-month high of 6.5 percent in July amid government tightening measures, according to the NBS data.On a monthly basis, the cost of living dipped 0.2 percent in December, while prices of entertainment, educational and cultural articles and services dropped 0.3 percent, the NBS said.Food prices, which account for nearly one third of the basket of goods in the nation's CPI calculation, went up 9.1 percent year-on-year in December and 1.2 percent month-on-month, the NBS said.The December inflation figure was in line with the market expectation, as many economists forecast that the CPI would grow around 4 percent year-on-year in December.China's Producer Price Index (PPI), a major measure of inflation at the wholesale level, rose 1.7 percent in December year-on-year, further weakening from 2.7 a month earlier.China has made controlling prices a top priority last year and implemented a series of measures to address the issue, including tightening monetary policy, cracking down on speculation, increasing food supplies and reducing circulation costs.

BEIJING, Nov. 30 (Xinhua) -- China's efforts to fight AIDS are impressive and its experience can be shared, according to Michel Sidibe, executive director of the Joint United Nations Programme on HIV/AIDS (UNAIDS)."We have seen progress in terms of new infections. The number of people going into treatment is increasing and the mortality rate is going down very quickly in China," Sidibe said during an interview with Xinhua on Wednesday.Sidibe said he was impressed by the country's political leadership and commitment to controlling AIDS.According to UNAIDS, the country has reported a 60-percent reduction in deaths due to AIDS over the past eight years.New HIV infection cases in China have been reduced from 70,000 people annually in 2005 to around 48,000 in 2011, according to the country's health department."However, China's success will not only be measured by what it has done for the Chinese people," Sidibe said.China has successful experience in reducing new HIV infections among intravenous drug users, which can be shared with the rest of the world, particularly east Europe and south Asia where HIV infections among drug abusers is a major challenge, he said.Sidibe suggested that the country should work with the rest of the developing world, particularly Africa, in fighting AIDS.A partnership between China and Africa will make a "big, big difference" in reducing AIDS mortality rates and introducing new technology and perspectives in Africa, said the official who had worked for UN in several African countries for more than two decades.Admitting the challenges of funding AIDS control programs during the current global economic downturn, Sidibe called for global solidarity and increasing shared responsibilities among countries."It is a critical moment now. It is not a time to stop investment but to redouble our efforts, to make sure that we will continue to make progress in the fight against HIV," Sidibe said."Getting to Zero" has been chosen as the main theme of World AIDS Day for the next five years, referring to UNAIDS' vision of "zero new HIV infections, zero discrimination and zero AIDS-related deaths."Sidibe met with Li Congjun, president of the Xinhua News Agency, on Wednesday before the interview. The agency has launched a global media campaign in cooperation with UNAIDS to raise public awareness about HIV/AIDS."The partnership (with Xinhua) is not only about writing news about HIV. It is about helping people to change their attitude and make decisions to help protect themselves," Sidibe said.

SAN FRANCISCO, Nov. 21 (Xinhua) -- Hewlett-Packard Co. (HP) on Monday reported that its profit in the most recent quarter fell more than 90 percent with sales also declining.In the company's fourth quarter of fiscal 2011 ended Oct. 31, the company posted net earnings of 239 million U.S. dollars, compared with 2.54 billion dollars in the same period a year earlier.HP's net revenue for the quarter reached 32.1 billion dollars, down 3 percent year-on-year.Excluding one-time items, HP earned 1.17 dollars per share, which topped estimates of analysts.According to Thomson Reuters, analysts had expected earnings of 1.13 dollars per share on revenue of 32.05 billion dollars.It was the first earnings report since Meg Whitman took over as chief executive officer (CEO) of the information technology giant on Sept. 22, replacing Leo Apotheker."HP has a great opportunity to build on our strong hardware, software, and services franchises with leading market positions, customer relationships, and intellectual property," Whitman said in a statement after the earnings announcement."We need to get back to the business fundamentals in fiscal 2012, including making prudent investments in the business and driving more consistent execution," she added.

WASHINGTON, Dec. 7 (Xinhua) -- The use of two drugs never tried in combination before in ovarian cancer resulted in a 70 percent destruction of cancer cells already resistant to commonly used chemotherapy agents, say researchers at Mayo Clinic in Florida.Their report, published on-line Wednesday in Gynecologic Oncology, suggests that this combination, ixabepilone and sunitinib, might offer a much needed treatment option for women with advanced ovarian cancer.Neither drug is approved for use in ovarian cancer. Ixabepilone is a chemotherapy drug that, like other taxane drugs, targets the microtubules and stops dividing cells from forming a spindle. It has been approved for use in metastatic breast cancer. Sunitinib, approved for use in kidney cancer, belongs to a class of tyrosine kinase inhibitors that stops growth signals from reaching inside cancer cells.When caught at late stages, ovarian cancer is often fatal because it progressively stops responding to the chemotherapy drugs used to treat it."Women die from ovarian cancer because their tumors become resistant to chemotherapy, so a drug that might be able to reduce that resistance -- which may be what this combination of agents is doing -- would be a boon to treatment of this difficult cancer," says study coauthor Gerardo Colon-Otero.The finding also highlights the importance of the role of a molecule, RhoB, that the researchers say is activated by the drug duo. It might be a potential biomarker that may help identify patients who might benefit from such combination therapy, the researchers say.

来源：资阳报